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A B S T R A C T
Patients with advanced liver cirrhosis may develop a clinical syndrome characterized by a blunted
contractile responsiveness to stress and/or altered diastolic relaxation, called ‘‘cirrhotic cardiomyopa-
thy.’’ This syndrome, which is initially asymptomatic, is often misdiagnosed due to the presence of
symptoms that characterize other disorders present in patients with advanced liver cirrhosis, such as
exercise intolerance, fatigue, and dyspnea. Stress and other conditions such as liver transplantation and
transjugular intrahepatic portosystemic shunt (TIPS) may unmask this syndrome. Liver transplantation
in this group of patients results in a clinical improvement and can be a cure for the cardiomyopathy.
However, post-transplant prognosis depends on the identiﬁcation of cirrhotics with cardiomyopathy in
the pre-transplant phase; an early diagnosis of cirrhotic cardiomyopathy in the pre-transplant phase
may avoid an acute onset or worsening of cardiac failure after liver transplantation. Since a preserved left
ventricular ejection fraction may mask the presence of cirrhotic cardiomyopathy, the use of newer
noninvasive diagnostic techniques (i.e. tissue Doppler, myocardial strain) is necessary to identify
cirrhotics with this syndrome, in the pre-transplant phase. A pre-transplant treatment of heart failure in
cirrhotics with cardiomyopathy improves the quality of life in this phase and reduces the complications
during and immediately after liver transplantation. Since speciﬁc therapies for cirrhotic cardiomyopathy
are lacking, due to the absence of a clear understanding of the pathophysiology of the cardiomyopathy,
further research in this ﬁeld is required.
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Fifty years ago, after studies on a group of alcoholic cirrhotics
affected by increased cardiac output and other electrocardiographic
abnormalities, the proﬁles of a new nosological entity that, at the
workshop of Montreal (2005) was termed cirrhotic cardiomyopathy,
began to take shape [1]. This syndrome was originally deﬁned as a
‘‘chronic cardiac dysfunction in patients with cirrhosis, character-
ized by a blunted contractile responsiveness to stress and/or altered
diastolic relaxation with electrophysiological abnormalities, in the
absence of known cardiac disease.’’ Cirrhotic cardiomyopathy affects
both patients with portal hypertension and cirrhosis and is
characterized by intrinsic alterations in myocardial function [2].
The clinical consequence is the presence of a blunted cardiac
response which is initially evident only in stress conditions.
Knowing whether cirrhotics awaiting liver transplant are affected
by this syndrome is essential for the post-transplant prognosis.
Cardiologists may be asked to help hepatologists and surgeons in the
diagnosis and treatment of this syndrome before and after liver
transplantation.
In this paper, we want to emphasize the importance of an early
diagnosis of this syndrome in cirrhotics especially in those
awaiting liver transplant, in order to avoid acute onset or
worsening of cardiac failure after liver transplantation.
Epidemiology
Symptoms and signs of cirrhotic cardiomyopathy are difﬁcult to
identify since this syndrome is clinically silent until intercurrent
changes in demand occur (i.e. infection, transjugular intrahepatic
portosystemic shunt, transplantation). Therefore, the exact preva-
lence cannot be deﬁned.
However, some information might derive from the data on the
prevalence of QT interval prolongation in cirrhotics (25% in
cirrhosis Child Pugh class A vs 51% in Child Pugh class B, vs 60% in
Child Pugh class C); indeed, QT interval prolongation is considered
to be the earliest sign of cirrhotic cardiomyopathy [1,3].
Natural history
The natural history of this syndrome is not entirely character-
ized and the lack of symptoms, especially in the early phase of
cirrhosis, masks and delays its diagnosis that may only unmask
itself during the decompensation phase [1–3].
Delaying the diagnosis of this syndrome carries unfavorable
prognostic implications; therefore, an improvement in the
diagnostic methods in order to early identify those patients at
risk of developing this syndrome is desirable.
The presence of splanchnic arterial vasodilation, a characteristic
ﬁnding of cirrhotics, ofﬂoading the left ventricle, may mask the
presence of a blunted cardiac response in the initial phase of the
cardiomyopathy [1].
At present there are no therapeutic guidelines with regards to the
management of cirrhotic cardiomyopathy and the natural history of
the disease is unknown [4]. Moreover, the treatment of cirrhosis
complications, including ascites, hepatic encephalopathy, and
esophageal varices, has not modiﬁed the natural history of this
syndrome, whereas a signiﬁcant clinical difference has been shown
by transjugular intrahepatic portosystemic shunt (TIPS) and liver
transplantation, as they both cause a rapid increase in venous return;
which in turn favors the onset of heart failure and pulmonary
hypertension that unmasks the presence of cirrhotic cardiomyopa-
thy [1].
Clinical presentation
It is well established that cardiac function is modulated by
preload and afterload. Cirrhotics are clinically volume overloadedbut the concomitant splanchnic vasodilation leads to reduced
vascular resistances, reduced afterload, and consequent impaired
venous return. Indeed, cirrhotics are affected by low arterial
pressure and impaired exercise tolerance and fatigue. To compen-
sate for the reduced vascular resistance, a sympathetic activation
occurs; this increases cardiac contractility but also stimulates renal
sodium and water retention through the activation of the renin–
angiotensin–aldosterone system [1]. In cirrhotics without cardio-
myopathy, cardiac output is generally increased whereas, in
cirrhotics with cardiomyopathy, the presence of a blunted cardiac
response due to an impaired cardiac function causes a further
reduction in the mean arterial pressure [1].
This effect is particularly evident during exertion in which an
increased demand leads to a further reduction of the mean arterial
pressure and a reduction in exercise intolerance and increased
fatigue (Fig. 1).
The amount that a further reduction in systemic vascular
resistance and the subsequent reduction in the cardiac response
that each one contributes to worsen the symptoms is, however,
difﬁcult to establish.
An ensuing cardiomyopathy may aggravate renal hypoperfu-
sion thus contributing to further volume overload and pulmonary
congestion, a condition that severely worsens in cirrhotics
following TIPS or liver transplantation.
Indeed, heart failure symptoms develop only after TIPS or liver
transplantation, although most cirrhotics with advanced liver
disease are already affected by the cardiomyopathy.
Cardiomyopathy affecting cirrhotics has similar but also
different aspects from the common dilated cardiomyopathy that
is always characterized by a low cardiac output.
In cirrhotics affected by cardiomyopathy, in the initial phases, a
high-output heart failure may be also present [5,6].
Therefore, diagnostic methods may fail to reveal cardiac
abnormalities in physiological conditions. A normal cardiac output
on echocardiography in decompensated cirrhotics should not rule
out the diagnosis of cardiomyopathy but maybe make it more
likely.
Pathophysiology
A broad spectrum of cardiac abnormalities characterizes the
development of cardiomyopathy in cirrhotics and, although a
precise chronological sequence in which these impact on the
cardiomyocytes is lacking, a pivotal role may surely be attributed
to electrical abnormalities (QT-interval abnormalities, electrical
and mechanical dissociation, chronotropic incompetence) due to
defective K-channel function in ventricular cardiomyocytes as a
result of decreased K-current density and also due to autonomic
dysfunction, such as defects in the sympathetic nervous system
and vagal impairment [1,7].
All these alterations, although associated with a direct im-
pairment of cardiomyocyte function (see Table 1), are not free from
the profound alterations involving the liver and its principal effector
(hepatic stellate cell) during cirrhosis; this causes an exaggerated
production of extracellular matrix components and vasoconstrictive
mediators thus favoring mechanic and dynamic portal hypertension
[8,9]. In portal hypertension conditions, the intestinal recruitment of
leucocytes is delayed, the local immune response may not be able to
prevent the passage of bacteria from intestinal lumen to the
systemic circulation, and mesenteric lymph nodes are deranged to
retain and destroy bacteria [10–12]. The logical consequence is that
endotoxin or bacterial DNA may easily reach the systemic
circulation, causing liver endothelial dysfunction, imbalance of
the intrahepatic circulation, worsening of portal hypertension, and
hemodynamic complications, as those observed in studies on
cirrhotics in normal conditions and post-prandial phase [13–15].
Fig. 1. Clinical pathophysiology of cirrhotic cardiomyopathy. GI, gastrointestinal; LV, left ventricular; SVR, systemic vascular resistance; TIPS, transjugular intrahepatic
portosystemic shunt.
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duced by these alterations may be initially compensated by an
increase in heart rate and cardiac output (hyperdynamic circula-
tion through the activation of sympathetic nervous system and the
renin–angiotensin–aldosterone system) but, in the late stages, this
compensation may be lost by favoring a reduction of the preload
(relative hypovolemia) [16,17]. As a result, the blunted cardiac
response reduces renal perfusion favoring the development of
hepatorenal syndrome [18].
Indeed, although short-term sympathetic overdrive increases
cardiac performance, prolonged stimulation leads to the occur-
rence of cardiomyopathy [1].Table 1
Pathophysiology of cardiac abnormalities in cirrhotics with cardiomyopathy.
Cardiac abnormalities Pathophysiology
QT-interval prolongation – K+ channel abnormalities
– Sympatho adrenergic hyperactivity
Electrical and mechanical
dissociation
– K+ channel abnormalities
– Sympatho adrenergic hyperactivity
Diastolic dysfunction – Increased myocardial stiffness
– Left ventricular hypertrophy
– Myocardial ﬁbrosis
– Changes in cardiomyocyte plasma membrane
ﬂuidity
– Impaired calcium signaling in cardiomyocytes
Systolic dysfunction – Reduced myocardial reserve
– Impaired oxygen extraction (local imbalance
of nitric oxide)
– Alterations in cardiac energy metabolism
– Negative inotropic effects of endocannabinoids
– Peroxynitrite impairment production
– Changes in ventricular b-adrenoceptor
– Changes in ventricular muscarinic receptorsHowever, vascular remodeling in the conductive vessels,
consisting of a decrease in the thickness and the total area of
the vascular wall and in a reduction in the vessel ability to contract,
may reduce the afterload, thus masking a blunted cardiac
response; in this way the diagnosis of cirrhotic cardiomyopathy
may be delayed [1].
Prognosis, treatment, and screening
Since cirrhosis has an overall unfavorable prognosis, only liver
transplant may be the cure for cirrhosis and the associated
cardiomyopathy [1].
Cirrhotics with cardiomyopathy have an impaired cardiac
function and this further worsens the prognosis. Furthermore,
cirrhotic cardiomyopathy is an important cause of perioperative
morbidity and mortality for liver transplant recipients [4].
Initially, it may seem that medical treatment used for heart
failure can be adopted also in cirrhotic cardiomyopathy; however,
evidence has shown that the treatment used for common heart
failure is not useful for curing cirrhotic cardiomyopathy. Angio-
tensin-converting enzyme inhibitors (and vasodilators in general)
are not useful in conditions of severe systemic vasodilation such as
those observed in cirrhotics with cardiomyopathy. However, low-
dose angiotensin II receptor antagonists have demonstrated an
acceptable safety proﬁle and a positive effect on portal pressures,
in patients with compensated or decompensated liver cirrhosis
[19].
Beta-adrenergic blockers are usually given to cirrhotics for the
prevention of recurrent variceal bleed but data on their utility in
cirrhotic cardiomyopathy are lacking. However, the clear rationale
for using these drugs in cirrhotics with cardiomyopathy might be
their sympathetic overdrive, a key feature of the disease process. In
Table 2
Diagnostic methods for investigating cirrhotic cardiomyopathy.
Methods Signs
Electrocardiogram – Prolonged QT interval
Exercise test – Reduced exercise tolerance
Cardiopulmonary
exercise test
– Alteration of aerobic capacity (peak VO2) or
ventilatory efﬁciency (VE/VCO2 or OUES)
Six-minute walk test – Reduced tolerance
Echocardiography – Systolic dysfunction (LVEF < 55%)
– Diastolic dysfunction
– Left ventricular hypertrophy
– Diastolic dysfunction (mean E/E0 index > 10)
Exercise or dobutamine
stress echocardiography
– Reduced contractile reserve
Magnetic resonance – Systolic dysfunction (LVEF < 55%)
– Diastolic dysfunction (peak ﬁlling rate)
– Left ventricular hypertrophy
BNP/NT-proBNP – Elevated levels
A wave, peak late atrial ﬁlling velocity (A, cm s1); BNP, brain natriuretic
peptide; EDT, E wave deceleration time (m/s); E wave, peak early ﬁlling velocity
(E, cm s1); LVEF, left ventricular ejection fraction; OUES, oxygen uptake
efﬁciency slope; proBNP, prohormone brain natriuretic peptide; VE, ventilator
efﬁciency; VE/VCO2, minute ventilation/carbon dioxide production; VO2,
oxygen volume (oxygen consumption); VCO2, carbon dioxide production.
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blocking activity would appear better than non-selective alpha-
beta1/2 blockers, due to their ability to avoid further vasodilation.
However, recent studies showed that carvedilol, a non-selective
blocker that possess a-blocking activity on top of b1/b2 blockade,
is well tolerated and as effective, or even more effective, than
selective propranolol (selective b1/b2 blocker) in reducing portal
hypertension [20,21]. As for diuretics (loop-diuretics and aldoste-
rone antagonists) that are often given to cirrhotics with and
without cardiomyopathy to treat hypervolemia, insufﬁcient data
are available on whether such treatments affect the outcome in
cirrhotics with cardiomyopathy.
Despite the difﬁculty of diagnosing cirrhotic cardiomyopathy
and obtaining results from medical treatment, there would be the
need for screening cirrhotics and treating potential heart failure
signs, especially prior to liver transplantation.
Indeed, after liver transplantation, rapid hemodynamic changes
due to increased ﬁlling pressures may worsen a pre-existing
congestive heart failure. Almost 25% of patients undergoing liver
transplant have cardiovascular complications and a higher risk for
postoperative pulmonary edema [22,23]. In the pre-transplant
phase, screening of cirrhotic cardiomyopathy should be made in all
cirrhotics, independently of their Child-Pugh-Turcotte or Model for
End-Stage Liver Disease (MELD) classiﬁcations.
The investigation of cardiac function in cirrhotics awaiting liver
transplant is necessary to better plan the management of heart
failure immediately after transplantation. Indeed, cirrhotic car-
diomyopathy is a syndrome deeply linked to the chronic liver
disease as demonstrated by the fact that cardiac function improves
after liver transplant [24].
Pre-transplant investigative methods
The basic concept is to persist in monitoring cardiac function in
cirrhotics awaiting liver transplant since, in conditions of marked
vasodilation (hyperdynamic syndrome), only the ability to
increase cardiac output may avoid the post-transplant develop-
ment of heart failure [25].
Unfortunately, speciﬁc recommendations for the pre-transplant
assessment of liver transplant candidates are not provided by the
New York Heart and the American Heart Associations, although their
scores are useful means to classify heart failure in these patients;
however, both have established that cirrhotics with cardiac risk
factors selected for liver transplant should undergo an evaluation for
cardiovascular disease [26]. Furthermore, the American Association
for the Study of Liver Diseases recommends that all liver transplant
candidates must undergo transthoracic echocardiography. Since,
cardiac dysfunction in cirrhosis seems not to be associated with the
severity of liver disease [27], both an accurate patient selection for
liver transplant [28,29] and a precise investigation for cirrhotic
cardiomyopathy are mandatory. Indeed, cirrhotic cardiomyopathy
may inﬂuence the outcome after liver transplantation [30–32];
moreover, liver transplantation may be responsible for additional
intra- and postoperative short- and long-term cardiac morbidity
[33].
To date most transplant liver centers screen for cardiac
characteristics required to receive a liver transplant in cirrhotics
by means of electrocardiography and echocardiography.
Indeed, decompensated cirrhotics with a high degree of portal
hypertension have a prolonged QT interval, due to electrolyte
disturbances or the use of QT interval-prolonging drugs, that need
correction [34]. Although, in normal hemodynamic conditions,
echocardiography is an excellent tool to assess the presence of
systolic or diastolic dysfunction, generally cirrhotics are affected
by a hyperdynamic syndrome; this hemodynamic disturbance
inﬂuences the cardiac load and makes an accurate evaluation ofcardiac function through conventional echocardiography more
difﬁcult [34].
Although, tissue Doppler imaging (TDI) may overcome this
problem by directly measuring the velocity of myocardial
displacement, and assessing left ventricular ﬁlling dynamics
[35], other diagnostic tools and indices may give useful informa-
tion about the presence of cirrhotic cardiomyopathy, helping to
stage the degree of cardiac dysfunction [36].
In Table 2, we summarize the role of diagnostic tools in the pre-
transplant investigation of cirrhotic cardiomyopathy.
Special attention should be given to cirrhotics with preopera-
tive elevated right-sided cardiac pressures, as well as older
patients, that have shown a greater risk for developing heart
failure after liver transplantation [37].
Optimization of therapy, using beta-blockers and diuretics
(including aldosterone-antagonists), should be done in all cirrho-
tics with heart failure signs.
Post-transplant phase
Immediately after liver transplantation, there is a signiﬁcant
stress on the cardiovascular system, with changes in preload and
afterload due to ﬂuid infusion and clamping of the hepatic vein
[38]. The heart of patients with cirrhotic cardiomyopathy is unable
to manage this situation, thus unmasking an underlying myocar-
dial contractile responsiveness.
In this situation, prompt ﬂuid management and cardiac
monitoring through transesophageal echocardiography and/or
pulmonary artery catheterization, are needed. Due to liver
denervation, transplant cirrhotics have been demonstrated to
have a different response to propranolol administration compared
to that of nontransplant cirrhotics [39]. Indeed, they showed lower
baseline hepatic vein pressure gradient (HVPG) values but similar
HVPG responses to propranolol infusions compared to nontrans-
plant cirrhotics [39]. Conversely to nontransplant cirrhotics, in
transplant cirrhotics, propranolol increased the systemic vascular
resistance and arterial pressure [39].
Conﬂicting results emerge on the time necessary to restore
hemodynamics in the post-transplant phase, but general accor-
dance exists on the fact that liver transplantation results in
correction of portal hypertension and reversal of hyperdynamic
syndrome [40,41].
Fig. 2. Diagnostic algorithm and treatment for patients with cirrhotic cardiomyopathy awaiting liver transplantation. ACE-inh, angiotensin-converting enzyme inhibitors;
BNP, brain natriuretic peptide; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CPET, cardio pulmonary exercise
test; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NT-proBNP, N terminal prohormone brain natriuretic peptide; 6MWT, six-minute walk test.
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phase is reported, due to the lack of accurate pretransplant
investigations or to the fact that none of these would be able to
sufﬁciently predict postoperative cardiac complications [42].
Two studies, investigating the cardiac function for up to
3 months after liver transplant in patients, demonstrated in the
ﬁrst case a diastolic function deterioration, and in the second case,
a ventricular dysfunction [43,44].
Another study showed that increased B-type natriuretic
peptide levels in the post-transplant phase returned to normal
values after 1 week [45].
A further study demonstrated a restoration in the QT interval
time after 3 months from liver transplantation [46]. A signiﬁcant
improvement in wall thickness, in diastolic function, in the systolic
response, and exercise capacity during stress was observed after
6 months from liver transplant [24]. Of value, the current opinion is
that cardiac dysfunction may last from a minimum of a few days
until a period of 6 months [47]. Clinical management of cirrhotic
cardiomyopathy in the pre-transplant phase, during, and after liver
transplant is crucial to assure a good prognosis. Overall, these
studies have their own limitations, but they all consistently
demonstrate an improvement in cardiac performance after liver
transplant, thus establishing that transplantation may be the cure
for cirrhotic cardiomyopathy.
Conclusions
Early clinical and diagnostic investigations to identify signs of
cardiomyopathy in cirrhotics undergoing liver transplant are
mandatory to avoid the worsening of cardiovascular hemodynam-
ics in the post-transplant phase.
Here, we propose a diagnostic algorithm to guide clinicians in
their daily practice (Fig. 2).
Due to the reversal of the hyperdynamic syndrome following
liver transplant, the prognosis may be good provided we prevent
the development of heart failure, which remains the most common
complication in patients receiving a liver transplant and is
therefore a cause for prolonged hospitalization and death.Although the American College of Cardiology/American Heart
Association has not given speciﬁc strategies to manage cirrhotic
cardiomyopathy, we recommend to follow the heart failure
guidelines for the treatment of cirrhotics affected by cardiomyop-
athy, with consideration for special conditions in patients with
markedly reduced systemic vascular resistance [48].
Advances in research will hopefully envisage more speciﬁc
therapeutic strategies, so that improved prognostic perspectives
may be assured to cirrhotics, during and following liver transplan-
tation.
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